Sencilia secures €450k subsidy from Health-Holland

We’re pleased to share that Sencilia has been awarded up to €450k in R&D funding from Health~Holland’s MKB program. This funding will accelerate Sencilia’s development of their groundbreaking ‘Rely-V’ IV infusion monitoring technology, designed to improve safety in neonatal and pediatric intensive care units (NICUs and PICUs).

Infusion therapy in NICUs and PICUs can be highly unpredictable, with over 60% of IV infusions experiencing flow rate errors that current systems fail to detect. These inaccuracies are particularly dangerous at the low flow rates needed for vulnerable patients, where even small deviations can lead to severe consequences, such as neurodevelopmental impairments. Sencilia’s ‘Rely-V’ aims to solve this issue by providing real-time monitoring of IV flow rates, instantly alerting clinicians to any discrepancies and helping prevent adverse drug events.

In collaboration with experts in nanofabrication (Prof. Dr. Ajay Kottapalli) and mechatronics (Prof. Dr. Bayu Jayawardhana) at the University of Groningen, Sencilia will focus on overcoming the key technical challenges of low-rate accuracy, sensor stability, and seamless integration with commercial IV systems. The Erasmus MC NICU/PICU team will also contribute to the project, helping ensure that ‘Rely-V’ meets the rigorous safety standards required for clinical validation.

By the project’s end, Sencilia aims to have a fully-functional prototype of ‘Rely-V’ that’s ready for clinical testing, advancing the technology readiness level and bringing safer IV infusion therapy one step closer to reality for our youngest and most vulnerable patients.

Source: Sencilia, Health Holland